<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Mild <z:hpo ids='HP_0002045'>hypothermia</z:hpo> renders potent neuroprotection against <z:hpo ids='HP_0011009'>acute</z:hpo> brain injury </plain></SENT>
<SENT sid="1" pm="."><plain>Recent reports show that <z:chebi fb="3" ids="16335">adenosine</z:chebi> 5'-monophosphate (<z:chebi fb="47" ids="16027,28971">AMP</z:chebi>) plays a role in thermoregulation and induces <z:hpo ids='HP_0002045'>hypothermia</z:hpo> in mice </plain></SENT>
<SENT sid="2" pm="."><plain>Therefore, this study sought to determine whether <z:chebi fb="47" ids="16027,28971">AMP</z:chebi> induces <z:hpo ids='HP_0002045'>hypothermia</z:hpo> in rats and to study its collective effects on <z:hpo ids='HP_0002637'>cerebral ischemia</z:hpo> induced by 2-h middle cerebral <z:mp ids='MP_0006134'>artery occlusion</z:mp> </plain></SENT>
<SENT sid="3" pm="."><plain>An intraperitoneal injection of <z:chebi fb="47" ids="16027,28971">AMP</z:chebi> induced <z:hpo ids='HP_0002045'>hypothermia</z:hpo> dose-dependently </plain></SENT>
<SENT sid="4" pm="."><plain>At the dose of 4 mmol/kg, <z:chebi fb="47" ids="16027,28971">AMP</z:chebi> induced promising mild <z:hpo ids='HP_0002045'>hypothermia</z:hpo> for 2.5 h </plain></SENT>
<SENT sid="5" pm="."><plain>Unexpectedly, the <z:chebi fb="47" ids="16027,28971">AMP</z:chebi>-induced <z:hpo ids='HP_0002045'>hypothermia</z:hpo> failed to reduce <z:mpath ids='MPATH_124'>infarct</z:mpath> volume after <z:e sem="disease" ids="C0007786" disease_type="Disease or Syndrome" abbrv="">brain ischemia</z:e>; instead, it exaggerated the ischemic damage, indicated by an increased <z:mpath ids='MPATH_124'>infarct</z:mpath> volume, as well as increased incidences of hemorrhagic transformation, <z:hpo ids='HP_0001250'>seizure</z:hpo>, and animal <z:hpo ids='HP_0011420'>death</z:hpo> </plain></SENT>
<SENT sid="6" pm="."><plain>Physiologic parameter monitoring revealed that <z:chebi fb="47" ids="16027,28971">AMP</z:chebi> causes profound <z:hpo ids='HP_0002615'>hypotension</z:hpo>, leading to <z:e sem="disease" ids="C1695782" disease_type="Disease or Syndrome" abbrv="">cerebral hypoperfusion</z:e> </plain></SENT>
<SENT sid="7" pm="."><plain>Furthermore, <z:chebi fb="47" ids="16027,28971">AMP</z:chebi> administration resulted in severe <z:hpo ids='HP_0003074'>hyperglycemia</z:hpo>, <z:hpo ids='HP_0001942'>metabolic acidosis</z:hpo>, and <z:hpo ids='HP_0002901'>hypocalcemia</z:hpo> </plain></SENT>
<SENT sid="8" pm="."><plain>In addition, western blots showed early dephosphorylation and degradation of <z:chebi fb="47" ids="16027,28971">AMP</z:chebi>-activated kinase in the ischemic cortex in <z:chebi fb="47" ids="16027,28971">AMP</z:chebi>-treated rats </plain></SENT>
<SENT sid="9" pm="."><plain>Taken together, our findings suggest that <z:chebi fb="47" ids="16027,28971">AMP</z:chebi> induces <z:hpo ids='HP_0002045'>hypothermia</z:hpo> in rats, probably by limiting cellular access to <z:chebi fb="105" ids="17234">glucose</z:chebi> </plain></SENT>
<SENT sid="10" pm="."><plain>However, the potential neuroprotection of <z:chebi fb="47" ids="16027,28971">AMP</z:chebi>-mediated <z:hpo ids='HP_0002045'>hypothermia</z:hpo> against <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e> was overwhelmed by the detrimental effects of <z:hpo ids='HP_0002615'>hypotension</z:hpo> and <z:hpo ids='HP_0003074'>hyperglycemia</z:hpo>, thus making <z:chebi fb="47" ids="16027,28971">AMP</z:chebi> an unlikely agent for inducing <z:hpo ids='HP_0002045'>hypothermia</z:hpo> to protect the brain against ischemic injury </plain></SENT>
</text></document>